Clinical Trial Update: Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dasatinib for unresectable or metastatic squamous cell carcinoma of the skin and Rai stage 0-I chronic lymphocytic leukemia; trial resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Squamous Cell Carcinoma of the Skin

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin | Phase 2 | Status: COMPLETED | Results posted: 2015-03-20